DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A

INTRODUCTION: Emicizumab effectively prevents bleeding in people with haemophilia A (PwHA), but is a burden for national healthcare budgets and consequently may limit access. According to the drug label, dosing of emicizumab is based on body weight with fixed intervals of 7, 14 or 28 days, which lea...

Descripción completa

Detalles Bibliográficos
Autores principales: Donners, Anouk, van der Zwet, Konrad, Egberts, Antoine C G, Fijnvandraat, Karin, Mathôt, Ron, Kruis, Ilmar, Cnossen, Marjon H, Schutgens, Roger, Urbanus, Rolf T, Fischer, Kathelijn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410934/
https://www.ncbi.nlm.nih.gov/pubmed/37369395
http://dx.doi.org/10.1136/bmjopen-2023-072363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410934/
https://www.ncbi.nlm.nih.gov/pubmed/37369395
http://dx.doi.org/10.1136/bmjopen-2023-072363

Ejemplares similares